Gland Pharma has received approval from the United States Food and Drug Administration (USFDA) for plerixafor injection single-dose vial product.
The product is bio-equivalent and therapeutically equivalent to the reference listed drug Mozobil (plerixafor) from Genzyme Corporation, a Sanofi company.
It is a haematopoietic stem cell mobiliser indicated in combination with filgrastim to mobilise haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin’s lymphoma or multiple myeloma.
The Hyderabad-based company expects to launch the product through its marketing partner in FY25. According to IQVIA, the product had US sales of approximately $152 million for the 12 months ending January 2024, a release said.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.